Core Viewpoint - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey, aiming for financial independence through investments [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since around 2009 [1]. - The blog "Kody's Dividends" was launched in July 2018 to document the author's financial independence journey through dividend growth investing [1]. - The author credits the blog for introducing them to the Seeking Alpha community as an analyst [1].

Core Insights - The article discusses the author's journey in dividend growth investing and the establishment of a blog that documents this journey towards financial independence [1]. Group 1 - The author has been investing since September 2017 and has a long-standing interest in dividend investing since 2009 [1]. - The blog "Kody's Dividends" was launched in July 2018 to share insights and experiences related to dividend growth investing [1]. - The author credits the blog for introducing them to the Seeking Alpha community as an analyst [1].

Core Viewpoint - Abbott Healthcare, an Indian drugmaker, is under investigation for the alleged misuse of its codeine-based cough syrup, which is known to be prone to abuse by addicts [1] Group 1: Company Overview - Abbott Healthcare's supply chain is currently being scrutinized as part of a broader investigation [1] Group 2: Industry Context - The investigation highlights concerns regarding the potential abuse of codeine-based medications within the pharmaceutical industry [1]

Core Viewpoint - Abbott Laboratories' shares fell over 9% intra-day following fourth-quarter earnings that met expectations but missed revenue targets, along with weaker guidance for the first quarter [1] Financial Performance - Adjusted earnings per share for the quarter were $1.50, aligning with analyst estimates [2] - Revenue totaled $11.46 billion, below the consensus forecast of $11.8 billion, with total sales increasing by 4.4% on a reported basis and 3.0% organically [2] - Organic growth, excluding COVID-19 testing-related sales, was 3.8% compared to the prior-year quarter [2] Segment Performance - The Medical Devices segment showed strong results, with revenue increasing by 12.3% to $5.68 billion [3] - Diabetes Care sales, including continuous glucose monitoring products, rose by 14.5% to $2.13 billion [3] - Nutrition revenue declined by 8.9% to $1.94 billion due to lower volumes and strategic pricing actions [3] - Diagnostics revenue fell by 2.5% to $2.46 billion, attributed to reduced demand for COVID-19 testing [3] Future Guidance - For the first quarter of 2026, Abbott projected adjusted earnings per share of $1.12 to $1.18, below the analyst consensus of $1.20 [2] - For the full year 2026, Abbott forecasted organic sales growth of 6.5% to 7.5% and adjusted earnings per share of $5.55 to $5.80, exceeding the analyst consensus of $5.17 and representing approximately 10% growth at the midpoint [4]

Core Insights - The medical-products maker experienced a significant decline in its stock price following disappointing quarterly profit and sales figures [1] Company Performance - The company's quarterly profit and sales figures did not meet investor expectations, leading to a drop in share value [1]

Abbott’s stock has fallen by over 7% despite reporting strong fiscal year 2025 (FY25) revenues of $44.32bn, representing a 5.7% increase on FY24. The fall of the healthcare giant’s stock primarily appears to be down to its Q4 2025 financials, which were released alongside the FY25 financials ahead of market open on 22 January. For Q4 2025, Abbott achieved revenues of $11.46bn, falling short of analysts’ expectations of $11.80bn, according to London Stock Exchange Group (LSEG) data seen by Reuters. Abbo ...

Labor Market - Initial Jobless Claims came in at +200K, which is 8K below expectations and a slight increase from the previous week's revised figure of +199K [1] - The four-week average of new jobless claims is now +202K, which is 15K lower than the previous four weeks [1] - Continuing Claims reached 1.85 million, down from 1.884 million the previous week, marking the second-lowest level since last year's Memorial Day to Thanksgiving period [2] Economic Growth - Q3 GDP was revised up to +4.4%, the highest single quarter since +4.7% in Q3 of 2023, driven by increases in exports, investments, and inventories [3] Earnings Reports - GE Aerospace reported Q4 earnings of $1.57 per share, beating estimates of $1.44, with revenues of $11.87 billion, surpassing expectations by 5.38%, although shares are down -3% due to slowing revenue growth [4] - Procter & Gamble's fiscal Q2 earnings were $1.88, slightly above estimates, while revenues were $22.21 billion, falling short by -0.36% [5] - Abbott Labs met earnings estimates of $1.50 per share but fell short on revenue projections at $11.46 billion, leading to a -7.2% drop in shares [6] - Freeport-McMoRan reported earnings of 47 cents per share, exceeding the estimated 28 cents, with revenues of $5.63 billion, surpassing expectations of $5.18 billion, and shares are up slightly [7] Upcoming Earnings - Major companies such as Intel, Intuitive Surgical, and Capital One are set to release earnings after today's close, all currently holding Zacks Rank 3 (Hold) ratings [8]

Market Overview - U.S. stocks experienced an upward trend, with the Nasdaq Composite increasing by over 200 points on Thursday [1] - The Dow rose by 0.78% to 49,462.35, the NASDAQ gained 0.94% to 23,443.19, and the S&P 500 increased by 0.63% to 6,918.78 [1] Company Performance - Abbott Laboratories (NYSE:ABT) saw its stock decline by over 7% after reporting fourth-quarter 2025 sales of $11.46 billion, which fell short of the consensus estimate of $11.80 billion [2] - The sales represented a 4.4% increase on a reported basis and a 3% increase on an organic basis, or 3.8% when excluding COVID-19 testing-related sales [2] - Abbott's adjusted earnings were reported at $1.50, aligning with Wall Street estimates [3] Sector Performance - Communication services shares increased by 1.3% on Thursday [1] - Utilities stocks experienced a decline of 0.5% in trading on Wednesday [1] Commodity Market - Oil prices decreased by 2.1% to $59.37, while gold prices increased by 0.6% to $4,864.60 [6] - Silver prices rose by 2.7% to $95.135, whereas copper prices fell by 0.4% to $5.7435 [6] Global Market Trends - European shares showed positive movement, with the eurozone's STOXX 600 gaining 1.09% and Spain's IBEX 35 Index rising by 1.01% [7] - Asian markets also closed higher, with Japan's Nikkei gaining 1.73% and India's BSE Sensex rising by 0.49% [8] Notable Stock Movements - 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) shares surged by 158% to $5.15 following a partnership announcement [9] - Eagle Bancorp, Inc. (NASDAQ:EGBN) shares increased by 18% to $28.25 after reporting better-than-expected fourth-quarter financial results [9] - Creative Media & Community Trust Corporation (NASDAQ:CMCT) shares rose by 52% to $4.4494 after closing the sale of its lending division [9] - C3is Inc. (NASDAQ:CISS) shares dropped by 37% to $0.088 due to a 1-for-20 reverse stock split announcement [9] - Mingteng International Corporation Inc. (NASDAQ:MTEN) shares fell by 34% to $0.020 after announcing a 1-for-200 reverse stock split [9] - POET Technologies Inc. (NASDAQ:POET) shares decreased by 12% to $7.35 following a $150 million offering of 20.690 million shares [9]

Labor Market - Initial Jobless Claims came in at +200K, which is 8K below expectations and a slight increase from the previous week's revised figure of +199K [1] - The four-week average of new jobless claims is now +202K, which is -15K lower than the previous four weeks [1] Continuing Claims - Continuing Claims reached 1.85 million, down from 1.884 million reported a week ago, marking the second-lowest tally since the previous high of 1.9+ million claims [2] Economic Growth - Q3 GDP was revised up by 10 basis points to +4.4%, the highest single quarter since +4.7% in Q3 of 2023, driven by increases in exports, investments, and inventories [3] Earnings Reports - GE Aerospace reported Q4 earnings of $1.57 per share, beating estimates of $1.44, with revenues of $11.87 billion, a +5.38% surprise, but shares are down -3% due to slowing revenue growth [4] - Procter & Gamble's fiscal Q2 earnings were $1.88, slightly above estimates, while revenues were $22.21 billion, falling short by -0.36% [5] - Abbott Labs met earnings estimates at $1.50 per share but fell short of revenue projections at $11.46 billion, leading to a -7.2% drop in shares [6] - Freeport-McMoRan reported earnings of 47 cents per share, exceeding the estimated 28 cents, with revenues of $5.63 billion, surpassing expectations of $5.18 billion [7] Upcoming Earnings - Major companies such as Intel, Intuitive Surgical, and Capital One are set to release earnings after today's close, all currently holding Zacks Rank 3 (Hold) ratings [8]

Core Insights - Abbott Laboratories reported fourth-quarter 2025 adjusted EPS of $1.50, aligning with estimates and showing an 11.9% increase from the previous year [1] - Full-year 2025 adjusted EPS was $5.15, reflecting a 10.3% year-over-year growth [1] - The company’s fourth-quarter revenues were $11.46 billion, a 4.4% increase year-over-year, but missed estimates by 2.8% [2] Financial Performance - The GAAP EPS for Q4 was $1.01, down from $5.27 in Q4 2024 [1] - Full-year 2025 worldwide sales reached $44.33 billion, up 5.7% year-over-year, but also missed estimates by 0.6% [2] - Gross profit for Q4 increased by 8.4% to $6.54 billion, with a gross margin expansion of 208 basis points to 57% [9] Segment Performance - Established Pharmaceuticals segment sales rose 9% to $1.38 billion, with organic sales growth of 7.1% [4] - Medical Devices segment sales increased 12.3% to $5.68 billion, driven by strong growth in Electrophysiology, Heart Failure, and Diabetes Care [5] - Nutrition sales declined 8.9% to $1.94 billion, with Pediatric Nutrition down 10.1% and Adult Nutrition down 8.2% [6][7] Future Guidance - For 2026, Abbott projects adjusted EPS between $5.55 and $5.80, with organic sales growth expected to be between 6.5% and 7.5% [11] - The first quarter of 2026 EPS is projected to be between $1.12 and $1.18 [11] Market Reaction - Following the earnings announcement, Abbott's stock fell 5.4% in pre-market trading [3] - The decline in Nutrition sales is attributed to lower sales volumes and strategic pricing actions [12]